AIM: This study aims to evaluate the impact of peripheral neuropathy symptoms throughout with monthly follow-ups during 4 months of paclitaxel treatment.
METHODS: This prospective cross-sectional study was conducted with 79 patients. The study population consisted of female patients with breast cancer between August 2018 and January 2019. ‘’Chemotherapy-Induced Peripheral Neuropathy Assessment Tool’’ and ‘’EORTC C30 Cancer Quality of Life Questionnaire’’ were applied with four follow-ups. The study was undertaken in accordance with the STROBE checklist for cross- sectional studies.
RESULTS: The Chemotherapy-Induced Peripheral Neuropathy Assessment Tool except for the general activity subdimension were statistically significant in the ratings of second, compared to first; third compared to first and second; fourth compared to first, second, and third follow-up periods. The overall mean of the EORTC C30 Cancer Quality of Life Questionnaire, functioning, symptom, and global health status were statistically significant in the evaluations of second, compared with first; third compared with first and second; fourth compared with first, second, and third follow-up periods.
CONCLUSION: Findings from this study suggest that the increase in neuropathy symptoms during cures negatively affects the quality of life.
Cite this article as: Kurt, B., Sipahi Karslı, Z., Çakmak Öksüzoğlu, B. Ö., Öztürk, E., Demirörs, N., & Dağ, O. (2023). Determination of the influence of peripheral neuropathy symptoms on quality of life in breast cancer patients: A cross-sectional study with four follow-ups. Florence Nightingale Journal of Nursing, 31(2), 75-81.